Plasma 25-hydroxyvitamin D and risk of premenstrual syndrome in a prospective cohort study

DSpace/Manakin Repository

Plasma 25-hydroxyvitamin D and risk of premenstrual syndrome in a prospective cohort study

Citable link to this page

 

 
Title: Plasma 25-hydroxyvitamin D and risk of premenstrual syndrome in a prospective cohort study
Author: Bertone-Johnson, Elizabeth R; Hankinson, Susan E; Forger, Nancy G; Powers, Sally I; Willett, Walter C; Johnson, Susan R; Manson, JoAnn E

Note: Order does not necessarily reflect citation order of authors.

Citation: Bertone-Johnson, Elizabeth R, Susan E Hankinson, Nancy G Forger, Sally I Powers, Walter C Willett, Susan R Johnson, and JoAnn E Manson. 2014. “Plasma 25-hydroxyvitamin D and risk of premenstrual syndrome in a prospective cohort study.” BMC Women's Health 14 (1): 56. doi:10.1186/1472-6874-14-56. http://dx.doi.org/10.1186/1472-6874-14-56.
Full Text & Related Files:
Abstract: Background: Moderate to severe premenstrual syndrome (PMS) affects 8–20 percent of premenopausal women. Previous studies suggest that high dietary vitamin D intake may reduce risk. However, vitamin D status is influenced by both dietary vitamin D intake and sunlight exposure and the association of vitamin D status with PMS remains unclear. Methods: We assessed the relation of plasma 25-hydroxyvitamin D (25OHD), total calcium and parathyroid hormone levels with risk of PMS and specific menstrual symptoms in a case–control study nested within the prospective Nurses’ Health Study II. Cases were 401 women free from PMS at baseline who developed PMS during follow-up (1991–2005). Controls were women not experiencing PMS (1991–2005), matched 1:1 with cases on age and other factors. Timed luteal phase blood samples were collected between 1996 and 1999 from cases and controls. We used conditional logistic regression to model the relation of 25OHD levels with risk of PMS and individual menstrual symptoms. Results: In analyses of all cases and controls, 25OHD levels were not associated with risk of PMS. However, results differed when the timing of blood collection vs. PMS diagnosis was considered. Among cases who had already been diagnosed with PMS at the time of blood collection (n = 279), 25OHD levels were positively associated with PMS, with each 10 nmol/L change in 25OHD associated with a 13% higher risk. Among cases who developed PMS after blood collection (n = 123), 25OHD levels were unrelated to risk of PMS overall, but inversely related to risk of specific menstrual symptoms. For example, each 10 nmol/L increase was associated with a significant 21% lower risk of breast tenderness (P = 0.02). Total calcium or parathyroid hormone levels were unrelated to PMS. Conclusions: 25OHD levels were not associated with overall risk of PMS. The positive association observed among women already experiencing PMS at the time of 25OHD measurement is likely due to confounding by indication related to use of dietary supplements to treat menstrual symptoms. Results from prospective analyses, which were less likely influenced by this bias, suggest that higher 25OHD levels may be inversely related to the development of specific menstrual symptoms.
Published Version: doi:10.1186/1472-6874-14-56
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3997197/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:12152850
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters